{"id":"https://openalex.org/W4368359461","doi":"https://doi.org/10.1080/21645515.2023.2204787","title":"Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial","display_name":"Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial","publication_year":2023,"publication_date":"2023-01-02","ids":{"openalex":"https://openalex.org/W4368359461","doi":"https://doi.org/10.1080/21645515.2023.2204787","pmid":"https://pubmed.ncbi.nlm.nih.gov/37140558","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10294743"},"language":"en","primary_location":{"id":"doi:10.1080/21645515.2023.2204787","doi":"https://doi.org/10.1080/21645515.2023.2204787","is_oa":true,"landing_page_url":"https://doi.org/10.1080/21645515.2023.2204787","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2204787?needAccess=true&role=button","source":{"id":"https://openalex.org/S2483136528","display_name":"Human Vaccines & Immunotherapeutics","issn_l":"2164-5515","issn":["2164-5515","2164-554X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Human Vaccines & Immunotherapeutics","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","datacite","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2204787?needAccess=true&role=button","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073464882","display_name":"P\u00edo L\u00f3pez","orcid":"https://orcid.org/0000-0001-5230-6595","observed_orcids":["https://orcid.org/0000-0001-5230-6595"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pio L\u00f3pez","raw_affiliation_strings":["Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica S.A.S","Department of Pediatrics, Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica S.A.S., Cali, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica S.A.S","institution_ids":[]},{"raw_affiliation_string":"Department of Pediatrics, Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica S.A.S., Cali, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103037309","display_name":"Eduardo L\u00f3pez\u2010Medina","orcid":"https://orcid.org/0000-0003-3066-5938","observed_orcids":["https://orcid.org/0000-0003-3066-5938"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eduardo L\u00f3pez-Medina","raw_affiliation_strings":["Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica S.A.S","Department of Pediatrics, Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica S.A.S., Cali, Colombia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica S.A.S","institution_ids":[]},{"raw_affiliation_string":"Department of Pediatrics, Centro de Estudios en Infectolog\u00eda Pedi\u00e1trica S.A.S., Cali, Colombia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091106598","display_name":"Xavier S\u00e1ez\u2010Llorens","orcid":"https://orcid.org/0000-0002-1149-5905","observed_orcids":["https://orcid.org/0000-0002-1149-5905"]},"institutions":[{"id":"https://openalex.org/I4210129707","display_name":"CEVAXIN","ror":"https://ror.org/03a1nz111","country_code":"PA","type":"facility","lineage":["https://openalex.org/I4210129707"]},{"id":"https://openalex.org/I4210134317","display_name":"Secretar\u00eda Nacional de Ciencia, Tecnolog\u00eda e Innovaci\u00f3n","ror":"https://ror.org/03gat5t60","country_code":"PA","type":"government","lineage":["https://openalex.org/I4210134317"]},{"id":"https://openalex.org/I4210153526","display_name":"Hospital del Ni\u00f1o","ror":"https://ror.org/05278be16","country_code":"PA","type":"healthcare","lineage":["https://openalex.org/I4210153526"]}],"countries":["PA"],"is_corresponding":false,"raw_author_name":"Xavier S\u00e1ez-Llorens","raw_affiliation_strings":["Cevaxin, The Panama Clinic","Hospital del Ni\u00f1o Dr. Jos\u00e9 Ren\u00e1n Esquivel","SNI, National Secretariat of Science, Technology and Innovation (SENACYT)","Department of Infectology, Cevaxin, The Panama Clinic, Panama City, Panama; Medicine (Pediatrics and Infectious Diseases), SNI, National Secretariat of Science, Technology and Innovation (SENACYT), Panama City, Panama","Infectious Diseases, Hospital del Ni\u00f1o Dr. Jos\u00e9 Ren\u00e1n Esquivel, Panama City, Panama","Medicine (Pediatrics and Infectious Diseases), SNI, National Secretariat of Science, Technology and Innovation (SENACYT), Panama City, Panama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cevaxin, The Panama Clinic","institution_ids":["https://openalex.org/I4210129707"]},{"raw_affiliation_string":"Hospital del Ni\u00f1o Dr. Jos\u00e9 Ren\u00e1n Esquivel","institution_ids":["https://openalex.org/I4210153526"]},{"raw_affiliation_string":"SNI, National Secretariat of Science, Technology and Innovation (SENACYT)","institution_ids":["https://openalex.org/I4210134317"]},{"raw_affiliation_string":"Department of Infectology, Cevaxin, The Panama Clinic, Panama City, Panama; Medicine (Pediatrics and Infectious Diseases), SNI, National Secretariat of Science, Technology and Innovation (SENACYT), Panama City, Panama","institution_ids":["https://openalex.org/I4210129707","https://openalex.org/I4210134317"]},{"raw_affiliation_string":"Infectious Diseases, Hospital del Ni\u00f1o Dr. Jos\u00e9 Ren\u00e1n Esquivel, Panama City, Panama","institution_ids":["https://openalex.org/I4210153526"]},{"raw_affiliation_string":"Medicine (Pediatrics and Infectious Diseases), SNI, National Secretariat of Science, Technology and Innovation (SENACYT), Panama City, Panama","institution_ids":["https://openalex.org/I4210134317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058702565","display_name":"Rodrigo DeAntonio","orcid":"https://orcid.org/0000-0003-2586-4115","observed_orcids":["https://orcid.org/0000-0003-2586-4115"]},"institutions":[{"id":"https://openalex.org/I4210129707","display_name":"CEVAXIN","ror":"https://ror.org/03a1nz111","country_code":"PA","type":"facility","lineage":["https://openalex.org/I4210129707"]}],"countries":["PA"],"is_corresponding":false,"raw_author_name":"Rodrigo deAntonio","raw_affiliation_strings":["Cevaxin, The Panama Clinic","Department of Infectology, Cevaxin, The Panama Clinic, Panama City, Panama"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cevaxin, The Panama Clinic","institution_ids":["https://openalex.org/I4210129707"]},{"raw_affiliation_string":"Department of Infectology, Cevaxin, The Panama Clinic, Panama City, Panama","institution_ids":["https://openalex.org/I4210129707"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112639278","display_name":"Taisei Masuda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086742","display_name":"Takeda (Switzerland)","ror":"https://ror.org/002ysmy84","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210086742","https://openalex.org/I44892455"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Taisei Masuda","raw_affiliation_strings":["Takeda Pharmaceuticals International AG","Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceuticals International AG","institution_ids":[]},{"raw_affiliation_string":"Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210086742"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072804583","display_name":"Paul M. Mendelman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I44892455","display_name":"Takeda (Japan)","ror":"https://ror.org/04hjbmv12","country_code":"JP","type":"company","lineage":["https://openalex.org/I44892455"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Paul M. Mendelman","raw_affiliation_strings":["Takeda Vaccines Inc","Clinical Development, Takeda Vaccines Inc., Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Vaccines Inc","institution_ids":["https://openalex.org/I44892455"]},{"raw_affiliation_string":"Clinical Development, Takeda Vaccines Inc., Cambridge, MA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085979449","display_name":"James R. Sherwood","orcid":"https://orcid.org/0009-0005-3448-4829","observed_orcids":["https://orcid.org/0009-0005-3448-4829"]},"institutions":[{"id":"https://openalex.org/I4210086742","display_name":"Takeda (Switzerland)","ror":"https://ror.org/002ysmy84","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210086742","https://openalex.org/I44892455"]}],"countries":["CH"],"is_corresponding":true,"raw_author_name":"James Sherwood","raw_affiliation_strings":["HilleVax GmbH","Takeda Pharmaceuticals International AG","Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland","Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HilleVax GmbH","institution_ids":[]},{"raw_affiliation_string":"Takeda Pharmaceuticals International AG","institution_ids":[]},{"raw_affiliation_string":"Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210086742"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112104842","display_name":"Frank Baehner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086742","display_name":"Takeda (Switzerland)","ror":"https://ror.org/002ysmy84","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210086742","https://openalex.org/I44892455"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Frank Baehner","raw_affiliation_strings":["Takeda Pharmaceuticals International AG","Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Takeda Pharmaceuticals International AG","institution_ids":[]},{"raw_affiliation_string":"Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210086742"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012683569","display_name":"Astrid Borkowski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086742","display_name":"Takeda (Switzerland)","ror":"https://ror.org/002ysmy84","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210086742","https://openalex.org/I44892455"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Astrid Borkowski","raw_affiliation_strings":["HilleVax GmbH","Takeda Pharmaceuticals International AG","Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland","Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HilleVax GmbH","institution_ids":[]},{"raw_affiliation_string":"Takeda Pharmaceuticals International AG","institution_ids":[]},{"raw_affiliation_string":"Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland","institution_ids":[]},{"raw_affiliation_string":"Clinical Development, HilleVax GmbH, Glattpark-Zurich, Switzerland; Clinical Development, Takeda Pharmaceuticals International AG, Zurich, Switzerland","institution_ids":["https://openalex.org/I4210086742"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5085979449"],"corresponding_institution_ids":["https://openalex.org/I4210086742"],"apc_list":{"value":2895,"currency":"EUR","value_usd":3175},"apc_paid":{"value":2895,"currency":"EUR","value_usd":3175},"fwci":4.8522,"has_fulltext":true,"cited_by_count":25,"citation_normalized_percentile":{"value":0.96288234,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"19","issue":"1","first_page":"2204787","last_page":"2204787"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10976","display_name":"Viral gastroenteritis research and epidemiology","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10976","display_name":"Viral gastroenteritis research and epidemiology","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11135","display_name":"Virology and Viral Diseases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/norovirus-vaccine","display_name":"norovirus vaccine","score":0.9129999876022339},{"id":"https://openalex.org/keywords/virus-like-particle-vaccine","display_name":"virus-like particle vaccine","score":0.9350000023841858},{"id":"https://openalex.org/keywords/bivalent-vaccine","display_name":"bivalent vaccine","score":0.7409999966621399},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.6790000200271606},{"id":"https://openalex.org/keywords/vaccine-tolerability","display_name":"vaccine tolerability","score":0.7300000190734863},{"id":"https://openalex.org/keywords/dose-finding","display_name":"dose-finding","score":0.7739999890327454},{"id":"https://openalex.org/keywords/young-children","display_name":"young children","score":0.6129999756813049},{"id":"https://openalex.org/keywords/antibody-persistence","display_name":"antibody persistence","score":0.5509999990463257},{"id":"https://openalex.org/keywords/aluminium-adjuvants","display_name":"alum adjuvant","score":0.597000002861023},{"id":"https://openalex.org/keywords/solicited-adverse-events","display_name":"solicited adverse events","score":0.6959999799728394}],"concepts":[{"id":"https://openalex.org/C2778750513","wikidata":"https://www.wikidata.org/wiki/Q1142751","display_name":"Norovirus","level":3,"score":0.8113793134689331},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7964282631874084},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.7230742573738098},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6279605627059937},{"id":"https://openalex.org/C2776620830","wikidata":"https://www.wikidata.org/wiki/Q4919211","display_name":"Bivalent (engine)","level":3,"score":0.6211630702018738},{"id":"https://openalex.org/C2776387124","wikidata":"https://www.wikidata.org/wiki/Q1475781","display_name":"Virus-like particle","level":4,"score":0.5368222594261169},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.5196132063865662},{"id":"https://openalex.org/C2991744798","wikidata":"https://www.wikidata.org/wiki/Q608510","display_name":"Double blind","level":4,"score":0.5137894749641418},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.461295485496521},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.36688917875289917},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.3290836215019226},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3027571439743042},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2742513418197632},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.23290053009986877},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21685999631881714},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.20934292674064636},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.18304234743118286},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.09020811319351196},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.08384767174720764},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0741407573223114},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.06756570935249329},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C544153396","wikidata":"https://www.wikidata.org/wiki/Q11426","display_name":"Metal","level":2,"score":0.0},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000071497","descriptor_name":"Immunogenicity, Vaccine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000914","descriptor_name":"Antibodies, Viral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007223","descriptor_name":"Infant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007273","descriptor_name":"Injections, Intramuscular","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D029322","descriptor_name":"Norovirus","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D058425","descriptor_name":"Vaccines, Virus-Like Particle","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":6,"locations":[{"id":"doi:10.1080/21645515.2023.2204787","doi":"https://doi.org/10.1080/21645515.2023.2204787","is_oa":true,"landing_page_url":"https://doi.org/10.1080/21645515.2023.2204787","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2204787?needAccess=true&role=button","source":{"id":"https://openalex.org/S2483136528","display_name":"Human Vaccines & Immunotherapeutics","issn_l":"2164-5515","issn":["2164-5515","2164-554X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Human Vaccines & Immunotherapeutics","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10294743","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10294743","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10294743/pdf/KHVI_19_2204787.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hum Vaccin Immunother","raw_type":"Text"},{"id":"pmid:37140558","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37140558","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Human vaccines & immunotherapeutics","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:doaj.org/article:8bdc7287d8f147359bc3a2bc68a345d5","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/8bdc7287d8f147359bc3a2bc68a345d5","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Human Vaccines & Immunotherapeutics, Vol 19, Iss 1 (2023)","raw_type":"article"},{"id":"pmh:oai:figshare.com:article/22762083","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Immunogenicity_and_tolerability_of_a_bivalent_virus-like_particle_norovirus_vaccine_candidate_in_children_from_6_months_up_to_4_years_of_age_A_phase_2_randomized_double-blind_trial/22762083","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"},{"id":"doi:10.6084/m9.figshare.22762083.v1","doi":"https://doi.org/10.6084/m9.figshare.22762083.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.22762083.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"}],"best_oa_location":{"id":"doi:10.1080/21645515.2023.2204787","doi":"https://doi.org/10.1080/21645515.2023.2204787","is_oa":true,"landing_page_url":"https://doi.org/10.1080/21645515.2023.2204787","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2204787?needAccess=true&role=button","source":{"id":"https://openalex.org/S2483136528","display_name":"Human Vaccines & Immunotherapeutics","issn_l":"2164-5515","issn":["2164-5515","2164-554X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Human Vaccines & Immunotherapeutics","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320338280","display_name":"Medical Research and Materiel Command","ror":"https://ror.org/03cd02q50"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4368359461.pdf","grobid_xml":"https://content.openalex.org/works/W4368359461.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W1908096245","https://openalex.org/W1995013137","https://openalex.org/W2011732215","https://openalex.org/W2015411778","https://openalex.org/W2115151801","https://openalex.org/W2118004842","https://openalex.org/W2129587137","https://openalex.org/W2160071779","https://openalex.org/W2170200960","https://openalex.org/W2464750180","https://openalex.org/W2770676570","https://openalex.org/W2936844166","https://openalex.org/W2999638541","https://openalex.org/W3005074212","https://openalex.org/W3005545953","https://openalex.org/W3007828236","https://openalex.org/W3108025162","https://openalex.org/W4280554955","https://openalex.org/W4282913861"],"related_works":["https://openalex.org/W4406339147","https://openalex.org/W4280554955","https://openalex.org/W2464750180","https://openalex.org/W2118004842","https://openalex.org/W2899150979","https://openalex.org/W4303183527","https://openalex.org/W2770676570","https://openalex.org/W3036973548","https://openalex.org/W2746313429","https://openalex.org/W2548452003"],"abstract_inverted_index":{"We":[0],"conducted":[1],"a":[2,86,165],"dose-finding":[3],"phase":[4],"2":[5],"study":[6],"of":[7,20,27,48,56,68,143,194,229],"the":[8,49,80,93,102,152,169,176,235],"HilleVax":[9],"bivalent":[10],"virus-like":[11],"particle":[12],"(VLP)":[13],"vaccine":[14],"candidate":[15],"(HIL-214)":[16],"in":[17,34,82,136,151,158,168,175,189],"two":[18],"cohorts":[19,139],"children,":[21],"6\u2013\u226412":[22],"months":[23],"and":[24,36,72,107,121,133,145,188,196,220],"1\u2013\u22644":[25],"years":[26],"age":[28,138,191],"(N":[29,89],"=":[30,90],"120":[31],"per":[32],"cohort),":[33],"Panama":[35],"Colombia":[37],"(ClinicalTrials.gov,":[38],"identifier":[39],"NCT02153112).":[40],"On":[41,76,123],"Day":[42,77,124,181,203],"1,":[43,118],"children":[44,81,239],"randomized":[45],"to":[46,100,202,233],"one":[47,127],"four":[50,57],"equal":[51],"groups":[52],"received":[53,85,96],"intramuscular":[54],"injections":[55,99],"different":[58],"HIL-214":[59,230],"formulations":[60,206],"containing":[61],"15/15,":[62],"15/50,":[63],"50/50,":[64],"or":[65],"50/150":[66],"\u03bcg":[67],"GI.1/GII.4c":[69],"genotype":[70],"VLPs":[71],"0.5":[73],"mg":[74],"Al(OH)3.":[75],"29,":[78,119,125],"half":[79,95],"each":[83],"group":[84,109],"second":[87,166],"vaccination":[88],"60),":[91],"while":[92],"other":[94],"saline":[97],"placebo":[98],"maintain":[101],"blind.":[103],"VLP-specific":[104],"ELISA":[105],"Pan-Ig":[106,132,195],"histo-blood":[108],"binding":[110],"antigen-blocking":[111],"antibodies":[112],"(HBGA)":[113],"were":[114,130,183,207],"measured":[115],"on":[116],"Days":[117],"57":[120,182],"210.":[122,204],"after":[126,164],"dose,":[128],"there":[129],"large":[131],"HBGA":[134,197],"responses":[135],"both":[137,190],"with":[140,210],"some":[141],"indication":[142],"dose-dependence,":[144],"higher":[146],"geometric":[147],"mean":[148],"titers":[149,159],"(GMT)":[150],"older":[153],"children.":[154],"A":[155],"further":[156],"increase":[157],"was":[160],"observed":[161],"28":[162],"days":[163],"dose":[167],"6\u2013\u226412-month-old":[170],"groups,":[171],"but":[172],"less":[173],"so":[174],"1\u2013\u22644-year-old":[177],"groups;":[178],"GMTs":[179,193],"at":[180],"broadly":[184],"similar":[185],"across":[186],"doses":[187],"groups.":[192],"persisted":[198],"above":[199],"baseline":[200],"up":[201],"All":[205],"well":[208],"tolerated":[209],"mostly":[211],"mild-to-moderate":[212],"transient":[213],"solicited":[214],"adverse":[215,224],"events":[216,225],"reported":[217],"by":[218],"parents/guardians,":[219],"no":[221],"vaccine-related":[222],"serious":[223],"occurred.":[226],"Further":[227],"development":[228],"is":[231],"warranted":[232],"protect":[234],"most":[236],"susceptible":[237],"young":[238],"against":[240],"norovirus.":[241]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":12},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":2}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2023-05-05T00:00:00"}